[1]卢建林,侯建全,杨永青.125I-脱氧尿苷治疗膀胱癌的实验与临床研究[J].国际放射医学核医学杂志,2009,33(3):154-158.[doi:10.3760/cma.j.issn.1673-4114.2009.03.007]
　LU Jian-lin,HOU Jian-quan,YANG Yong-qin.Experimental and clinical treatment of bladder cancer with 125I-iododeoxyuridine[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):154-158.[doi:10.3760/cma.j.issn.1673-4114.2009.03.007]
点击复制

125I-脱氧尿苷治疗膀胱癌的实验与临床研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
33
期数:
2009年第3期
页码:
154-158
栏目:
核素治疗
出版日期:
1900-01-01

文章信息/Info

Title:
Experimental and clinical treatment of bladder cancer with 125I-iododeoxyuridine
作者:
卢建林1;  侯建全2;  杨永青3
1. 苏州市立医院本部泌尿外科, 苏州 215002;
2. 苏州大学附属第一医院泌尿外科, 苏州 215001;
3. 苏州市立医院本部核医学科, 苏州 215002
Author(s):
LU Jian-lin1;  HOU Jian-quan2;  YANG Yong-qin3
1. Department of Urology, Suzhou Municipal Hospital, Suzhou 215002, China;
2. Department of Urology, the First Hospital Affiliated to Suzhou University, Suzhou 215001, China;
3. Department of Nuclear Medcine, Suzhou Municipal Hospital, Suzhou 215002, China
关键词:
碘苷; 碘放射性同位素; 膀胱肿瘤; 放射疗法
Keywords:
Idoxuridine; Iodine Radioisotopes; Bladder neoplasms; Radiotherapy
DOI:
10.3760/cma.j.issn.1673-4114.2009.03.007
摘要:
放射性核素通过电子俘获和(或)内转换衰变产生低能电子(<1 keV)的俄歇效应,掺入细胞DNA后具有显著的细胞毒性。125I-脱氧尿苷(125I-UdR)是将125I引入细胞核的有效载体,能特异性掺入S期细胞DNA。一系列研究表明,125I能更多地被肿瘤细胞吸收,而不是正常的分裂细胞,从而有效地治疗恶性病变。由于膀胱为一天然囊腔,具有独特的易灌注及观察性,膀胱灌注125I-UdR治疗膀胱癌,能高效、选择性杀伤肿瘤细胞,明显降低膀胱癌复发率,故可作为外科手术的辅助治疗手段,有希望成为一种安全、高效、不良反应小的治疗膀胱癌的新疗法。
Abstract:
Radionuclide can cause auger effect through disintegration low-energy electron (<1 keV) through electron entrapment and (or) internal conversion. Incorporation of Auger-electron emitters into the DNA have significant eytotoxicity, 125I-iododeoxyuridine (125I-UdR) is an efficient carrier inducting 125I to cell nucleolus, it is incorporated into DNA specificity only in S-phase cells. A series of studies show that 125I can absorb more likely to tumor cells, instead of the normal cell division, thus effectively splitting radiotherapy of malignant lesions. As bladder is a natural lumen, it has a unique easy perfusion and observational, 125I-UdR can kill effiently and selectively the cells of bladder tumour, reducing markedly the ratio of its recurrence of surgical treatment of patients with bladder cancer, so as to improve the survival rate. It can be used as a surgical adjuvant treatment method, is expected to be a safe, efficient and less adverse reaction the new therapies for bladder cancer treatment.

参考文献/References:

[1] Karagiannis TC, Lobachevsky PN, Martin RF. Cytotoxicity of an 125I-labelled DNA ligand. Acta Oncol, 2000, 39(6):681-685.
[2] Elmroth K, Stenerlöw B. DNA-incorporated 125I induces more than one double-strand break per decay in mammalian cells. Radial Res, 2005, 163(4):369-373.
[3] Casado FJ, Lostao MP, Aymerich I, et al. Nucleoside transporters in absorptive epithelia. J Physiol Biochem, 2002, 58(4):207-216.
[4] Bucheggter F, Vieira JM, Blaeuenstein P, et al. Preclinical Auger an gamma radiation dosimetry for lluorodeoxyuridine-enhanced turnout proliferation scintigraphy with [123I]iododeoxyuridine. Eur J Null Med Mol Imaging, 2003, 30(2):239-246.
[5] Taverna P, Hwang HS, Sehupp JE, et al. Inhibition of base exeision repair potentiates iododeoxyurdine-induced cytotoxicity and radiosensitization. Cancer Res, 2003, 63(4):838-846.
[6] Zackrisson B, Flvgare P. Gustafsson It, et al. Cell kinetic changes in human squamous cell carcinomas fluring radiotherapy studies using the the in vivo administration of two halogenated pyrimidines. Eur J Cancer, 2002, 38(8):1100-1106.
[7] Schneiderman MH, Schneiderman GS. Radioiododeoxyuridine in cancer therapy:an in vitro approach to developing in vivo strategies. J Nucl Med, 1996, 37(4 suppl):6S-9S.
[8] Baranowska-Kortylewicz J, Dalrymple GV, Harrison KA, et al. On tile safety of 5-[125I]iodo-2’-deoxyuridine-preclinical evaluation in swine. Acta Oncol. 1996, 35(7):925-933.
[9] Kassis AI, Adelstein SJ. Preclinical animal studies with radioiododeoxyuridine. J Nucl Med, 1996,374(suppl):10S-12S.
[10] Van den Abbeete AD, Tutrone RF, Berman RM, et al. Tumortargeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med, 1996, 37(2):315-320.
[11] Seo Y, Yan T, Schupp JE, et al. Differential radiosensitization in DNA mismatch repair-proficient and-deficient human colon cancer xenograits with 5-iodo-2-pyrimidinone-2’-deoxyribose. Clin Cancer Res, 2004, 10(22):7520-7528.
[12] Ou XH, Kuang AR, Peng X, et al. Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy. World J Gastroenterol, 2003, 9(8):1675-1678.
[13] Harrington K J, Syrigos KN, Uster PS, et al. Targeted radiosensitisation by pegylated liposome-encapsalated 3’, 5’-O-dipalmitoyl5-iodo-2’-deoxyuridine in a head and neck cancer xenograft model. Br J Cancer, 2004, 91(2):366-373.
[14] Kassis AI, Kirichian AM, Wang K, et al. Therapeutic potential of 5-[125I]iodo-2’-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol, 2004, 80(11-12):941-946.
[15] Okunieff P, Meyn RE, Teicher BA, et al. Report from the radiation oncology conunittee of the southwest oncology group (SWOG):research objectives workshop 2003. Am J Clin Oncol, 2003, 26(5):522-529.
[16] Harrison KA, Dahymple GV, Baranowskd-kortylewicz J, et al. Radiolabeled iododeoxyuridine:safety evaluation. J Nucl Med, 1996, 37(4 suppl):13S-16S.
[17] Mariani C, Cullecchi P, Baldassarri S, et al. Tumor uptake and mitotic activity pattern of 5-[125I]Iodo-2’-deoxyuridinc after intravesical in patients with bladder cancer. J Nucl Med, 1996, 37(4 suppl):16S-19S.
[18] Chiou RK, Dalrymple GV, Baranowska-Kortylewicz J, et al. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer. J Urol, 1999, 162(1):58-62.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]

备注/Memo

备注/Memo:
收稿日期:2009-02-11
通讯作者:杨永青,E-mail:chuanchuan458@126.com
更新日期/Last Update: 1900-01-01